Human anti-β-amyloid antibodies block β-amyloid fibril formation and prevent β-amyloid-induced neurotoxicity

Yansheng Du, Xing Wei, Richard Dodel, Norbert Sommer, Harald Hampel, Feng Gao, Zhizhong Ma, Liming Zhao, Wolfgang H. Oertel, Martin Farlow

Research output: Contribution to journalArticle

115 Citations (Scopus)

Abstract

The accumulation of β-amyloid (Aβ) in neuritic plaques is thought to be causative for the progression of Alzheimer's disease (AD). Recently, both active immunization and passive administration of Aβ antibodies dramatically attenuated amyloid plaque deposition, neuritic dystrophy, astrogliosis and behaviour deficits in transgenic animals. In addition, we and others have found that titres of naturally occurring anti-Aβ antibodies in the CSF of AD patients are significantly lower than those in age-matched controls. Treatment with intravenous immunoglobulins (a preparation that contained anti-Aβ antibodies) significantly lowered CSF levels of Aβ in non-demented patients. In this study, anti-Aβ antibodies were isolated from immunoglobulin preparations and these anti-Aβ antibodies strongly block fibril formation or disrupt formation of fibrillar structures. Furthermore, these antibodies almost completely prevented neurotoxicity of Aβ. In contrast, immunoglobulins depleted of anti-Aβ antibodies had little effect on Aβ fibril formation or protection of neuronal cells. This study supports the findings that human anti-Aβ antibodies may interfere with the pathogenesis of AD by more than one mechanism, and administration of polyclonal human anti-Aβ antibodies isolated from plasma is a potential therapeutic agent to prevent or slow down disease progression.

Original languageEnglish
Pages (from-to)1935-1939
Number of pages5
JournalBrain
Volume126
Issue number9
DOIs
StatePublished - Sep 1 2003

Fingerprint

Amyloid
Anti-Idiotypic Antibodies
Alzheimer Disease
Amyloid Plaques
Immunoglobulins
Genetically Modified Animals
Cytoprotection
Antibodies
Intravenous Immunoglobulins
Disease Progression
Vaccination
Therapeutics

Keywords

  • β-amyloid
  • Aβ antibodies
  • Alzheimer's disease
  • Immunotherapy
  • Neurotoxicity

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Human anti-β-amyloid antibodies block β-amyloid fibril formation and prevent β-amyloid-induced neurotoxicity. / Du, Yansheng; Wei, Xing; Dodel, Richard; Sommer, Norbert; Hampel, Harald; Gao, Feng; Ma, Zhizhong; Zhao, Liming; Oertel, Wolfgang H.; Farlow, Martin.

In: Brain, Vol. 126, No. 9, 01.09.2003, p. 1935-1939.

Research output: Contribution to journalArticle

Du, Y, Wei, X, Dodel, R, Sommer, N, Hampel, H, Gao, F, Ma, Z, Zhao, L, Oertel, WH & Farlow, M 2003, 'Human anti-β-amyloid antibodies block β-amyloid fibril formation and prevent β-amyloid-induced neurotoxicity', Brain, vol. 126, no. 9, pp. 1935-1939. https://doi.org/10.1093/brain/awg191
Du, Yansheng ; Wei, Xing ; Dodel, Richard ; Sommer, Norbert ; Hampel, Harald ; Gao, Feng ; Ma, Zhizhong ; Zhao, Liming ; Oertel, Wolfgang H. ; Farlow, Martin. / Human anti-β-amyloid antibodies block β-amyloid fibril formation and prevent β-amyloid-induced neurotoxicity. In: Brain. 2003 ; Vol. 126, No. 9. pp. 1935-1939.
@article{db3a73e664ce42d8a34eabec72693979,
title = "Human anti-β-amyloid antibodies block β-amyloid fibril formation and prevent β-amyloid-induced neurotoxicity",
abstract = "The accumulation of β-amyloid (Aβ) in neuritic plaques is thought to be causative for the progression of Alzheimer's disease (AD). Recently, both active immunization and passive administration of Aβ antibodies dramatically attenuated amyloid plaque deposition, neuritic dystrophy, astrogliosis and behaviour deficits in transgenic animals. In addition, we and others have found that titres of naturally occurring anti-Aβ antibodies in the CSF of AD patients are significantly lower than those in age-matched controls. Treatment with intravenous immunoglobulins (a preparation that contained anti-Aβ antibodies) significantly lowered CSF levels of Aβ in non-demented patients. In this study, anti-Aβ antibodies were isolated from immunoglobulin preparations and these anti-Aβ antibodies strongly block fibril formation or disrupt formation of fibrillar structures. Furthermore, these antibodies almost completely prevented neurotoxicity of Aβ. In contrast, immunoglobulins depleted of anti-Aβ antibodies had little effect on Aβ fibril formation or protection of neuronal cells. This study supports the findings that human anti-Aβ antibodies may interfere with the pathogenesis of AD by more than one mechanism, and administration of polyclonal human anti-Aβ antibodies isolated from plasma is a potential therapeutic agent to prevent or slow down disease progression.",
keywords = "β-amyloid, Aβ antibodies, Alzheimer's disease, Immunotherapy, Neurotoxicity",
author = "Yansheng Du and Xing Wei and Richard Dodel and Norbert Sommer and Harald Hampel and Feng Gao and Zhizhong Ma and Liming Zhao and Oertel, {Wolfgang H.} and Martin Farlow",
year = "2003",
month = "9",
day = "1",
doi = "10.1093/brain/awg191",
language = "English",
volume = "126",
pages = "1935--1939",
journal = "Brain",
issn = "0006-8950",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Human anti-β-amyloid antibodies block β-amyloid fibril formation and prevent β-amyloid-induced neurotoxicity

AU - Du, Yansheng

AU - Wei, Xing

AU - Dodel, Richard

AU - Sommer, Norbert

AU - Hampel, Harald

AU - Gao, Feng

AU - Ma, Zhizhong

AU - Zhao, Liming

AU - Oertel, Wolfgang H.

AU - Farlow, Martin

PY - 2003/9/1

Y1 - 2003/9/1

N2 - The accumulation of β-amyloid (Aβ) in neuritic plaques is thought to be causative for the progression of Alzheimer's disease (AD). Recently, both active immunization and passive administration of Aβ antibodies dramatically attenuated amyloid plaque deposition, neuritic dystrophy, astrogliosis and behaviour deficits in transgenic animals. In addition, we and others have found that titres of naturally occurring anti-Aβ antibodies in the CSF of AD patients are significantly lower than those in age-matched controls. Treatment with intravenous immunoglobulins (a preparation that contained anti-Aβ antibodies) significantly lowered CSF levels of Aβ in non-demented patients. In this study, anti-Aβ antibodies were isolated from immunoglobulin preparations and these anti-Aβ antibodies strongly block fibril formation or disrupt formation of fibrillar structures. Furthermore, these antibodies almost completely prevented neurotoxicity of Aβ. In contrast, immunoglobulins depleted of anti-Aβ antibodies had little effect on Aβ fibril formation or protection of neuronal cells. This study supports the findings that human anti-Aβ antibodies may interfere with the pathogenesis of AD by more than one mechanism, and administration of polyclonal human anti-Aβ antibodies isolated from plasma is a potential therapeutic agent to prevent or slow down disease progression.

AB - The accumulation of β-amyloid (Aβ) in neuritic plaques is thought to be causative for the progression of Alzheimer's disease (AD). Recently, both active immunization and passive administration of Aβ antibodies dramatically attenuated amyloid plaque deposition, neuritic dystrophy, astrogliosis and behaviour deficits in transgenic animals. In addition, we and others have found that titres of naturally occurring anti-Aβ antibodies in the CSF of AD patients are significantly lower than those in age-matched controls. Treatment with intravenous immunoglobulins (a preparation that contained anti-Aβ antibodies) significantly lowered CSF levels of Aβ in non-demented patients. In this study, anti-Aβ antibodies were isolated from immunoglobulin preparations and these anti-Aβ antibodies strongly block fibril formation or disrupt formation of fibrillar structures. Furthermore, these antibodies almost completely prevented neurotoxicity of Aβ. In contrast, immunoglobulins depleted of anti-Aβ antibodies had little effect on Aβ fibril formation or protection of neuronal cells. This study supports the findings that human anti-Aβ antibodies may interfere with the pathogenesis of AD by more than one mechanism, and administration of polyclonal human anti-Aβ antibodies isolated from plasma is a potential therapeutic agent to prevent or slow down disease progression.

KW - β-amyloid

KW - Aβ antibodies

KW - Alzheimer's disease

KW - Immunotherapy

KW - Neurotoxicity

UR - http://www.scopus.com/inward/record.url?scp=0041320819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041320819&partnerID=8YFLogxK

U2 - 10.1093/brain/awg191

DO - 10.1093/brain/awg191

M3 - Article

C2 - 12821522

AN - SCOPUS:0041320819

VL - 126

SP - 1935

EP - 1939

JO - Brain

JF - Brain

SN - 0006-8950

IS - 9

ER -